Shots:

• The US FDA has granted approval to Nourianz for use as an add-on treatment to levodopa/carbidopa and is based on clinical studies assessing Nourianz vs PBO in PD patients experiencing “OFF” episodes- administering a stable dose of levodopa/carbidopa with/out other PD therapies
• The four clinical study results demonstrated that adjunct to levodopa/carbidopa- istradefylline improves OFF time and is well tolerated among the patients
• Nourianz (PO) is a selective adenosine A2A receptor antagonist and is marketed under the trade name as Nouriast in Japan indicated for the improvement of the wearing-off phenomenon in patients with PD- since May 30- 2013

Click here to­ read full press release/ article | Ref: Kyowa Kirin | Image: WSJ